Finances:
David Brennan, Chief Executive Officer, said: “AstraZeneca has delivered a robust performance in an increasingly challenging market environment.” As of December 2nd, the stock prices are up +1.6% since September 7th at $45.93.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment